Stock A204840 GL PHARM TECH CORP.
Add to a list
To use this feature you must be a member
Log inSign up

GL Pharm Tech Corp. Share Price

Equities

A204840

KR7204840003

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
1,320 KRW +11.39% Intraday chart for GL Pharm Tech Corp. +11.86% +16.20%
06/03 W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund CI
06/03 GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd. CI

Financials

Sales 2022 16.73B 12.16M 1.01B Sales 2023 26.03B 18.93M 1.58B Capitalization 70.83B 51.5M 4.29B
Net income 2022 -790M -574K -47.85M Net income 2023 -3.75B -2.73M -227M EV / Sales 2022 3.34 x
Net Debt 2022 9.27B 6.74M 562M Net Debt 2023 13.65B 9.92M 827M EV / Sales 2023 3.25 x
P/E ratio 2022
-57.7 x
P/E ratio 2023
-18.9 x
Employees 22
Yield 2022 *
-
Yield 2023
-
Free-Float 77.33%
More Fundamentals * Assessed data

Chart GL Pharm Tech Corp.

Dynamic Chart

Latest news about GL Pharm Tech Corp.

W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund CI
GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd. CI
GL Pharm Tech to Raise 9.2 Billion Won via Share Issuance; Shares Decline 7% MT
GL Pharm Tech Corp. announced that it expects to receive KRW 9.199999458 billion in funding from W Science Co., Ltd. CI
W Science Co., Ltd. agreed to acquire a 14.7% stake in GL Pharm Tech Corp. CI
GL Pharm Tech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt CI
GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt CI
GL Pharm Tech Corp. announced that it expects to receive KRW 8.999999634 billion in funding from Ideal Private Equity Fund CI
GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd. CI
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd. CI
GL Pharm Tech Corp. announced that it has received KRW 1.000000534 billion in funding from Kuhnil Pharmaceutical Co., Ltd. CI
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000534 billion in funding from Kuhnil Pharmaceutical Co., Ltd. CI
GL Pharm Tech Corp. announced that it has received KRW 3.1 billion in funding from Unione Communications Co., Ltd. CI
GL Pharm Tech Corp. announced that it expects to receive KRW 3.1 billion in funding from Unione Communications Co., Ltd. and other investors CI
More news

Quotes and Performance

1 day+11.39%
1 week+11.86%
Current month-3.15%
1 month+0.38%
3 months+17.44%
6 months+28.03%
Current year+16.20%
More quotes

Highs and lows

1 week
1 165.00
Extreme 1165
1 325.00
1 month
1 112.00
Extreme 1112
1 393.00
Current year
1 100.00
Extreme 1100
1 540.00
1 year
705.00
Extreme 705
1 830.00
3 years
655.00
Extreme 655
1 830.00
5 years
390.00
Extreme 390
3 350.00
10 years
390.00
Extreme 390
8 450.00
More quotes

Managers and Directors - GL Pharm Tech Corp.

Managers TitleAgeSince
Hun-Sik Wang CEO
 Chief Executive Officer 52 01/02/01
Jun-Sang Park CTO
 Chief Tech/Sci/R&D Officer 52 01/02/01
Dae-Jong Park AUD
 Comptroller/Controller/Auditor 51 01/15/01
Members of the board TitleAgeSince
Hun-Sik Wang CEO
 Chief Executive Officer 52 01/02/01
Jun-Sang Park CTO
 Chief Tech/Sci/R&D Officer 52 01/02/01
Jae-Kyung Park BRD
 Director/Board Member - -
More insiders

Quotes

Date Price Change Volume
26/24/26 1,320 +11.39% 607,003
25/24/25 1,185 -0.50% 68,690
24/24/24 1,191 +1.79% 61,570
23/24/23 1,170 -0.68% 122,144
22/24/22 1,178 -0.17% 118,477

End-of-day quote Korea S.E., April 26, 2024

More quotes

Company Profile

GL Pharm Tech Corp., formerly IBKS No.2 Special Purpose Acquisition Company, is a Korea-based company mainly engaged in the research and development of pharmaceutical products.
Sector
Biotechnology & Medical Research
Calendar
10/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GL PHARM TECH CORP. Stock GL Pharm Tech Corp.
+16.20% 73.55M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A204840 Stock